Table 2. Patient characteristics in the propensity score–matched cohort.
| Group | |||
|---|---|---|---|
| PCI (N = 19) | non-PCI (N = 19) | p value | |
| Age at diagnosis, years | 0.429 | ||
| Median | 72 (56–81) | 71 (56–82) | |
| Gender | 1 | ||
| Male | 12 (68) | 11 (58) | |
| Female | 7 (32) | 8 (42) | |
| Performance status | 1 | ||
| 0 | 12 (63) | 11 (58) | |
| 1 | 7 (37) | 7 (37) | |
| 2 | 0 (0) | 1 (5) | |
| Smoking history | 0.487 | ||
| Current/Former | 19 (100) | 17 (89) | |
| Never | 0 (0) | 2 (11) | |
| Stage | 0.270 | ||
| IIA | 3 (16) | 1 (5) | |
| IIB | 1 (5) | 5 (26) | |
| IIIA | 10 (53) | 6 (32) | |
| IIIB | 4 (21) | 6 (32) | |
| IIIC | 1 (5) | 1 (5) | |
| Platinum-containing drug | 0.476 | ||
| CDDP | 15 (79) | 12 (63) | |
| CBDCA | 4 (21) | 7 (37) | |
| TRT method | 0.063 | ||
| Concurrent | 17 (89) | 11 (58) | |
| Sequential | 2 (11) | 8 (42) | |
| Response to treatment | 0.170 | ||
| CR | 9 (47) | 4 (21) | |
| PR | 10 (53) | 15 (79) | |
Abbreviation: PCI, prophylactic cranial irradiation; CDDP, cisplatin; CBDCA, carboplatin; CR, complete response; PR, partial response.